Protein Assays Market To Show Steady Growth, 2023

 Protein assays are utilized in life science research to detect the presence of protein in a sample. There are various assays available in the market differing from each other on the basis of sensitivity, principle and methodology. The macro factors such as sample size, amount, interfering agents and reproducibility are also responsible for its quantification. Protein assays rely mostly on color change i.e. colorimetric assay and use of standard protein such as immunoglobulin G (IgG) or bovine serum albumin (BSA). Protein quantification is the most important step before separation and analysis by electrophoresis or chromatography or any other immunochemical techniques.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/5091

The use of protein assays for early diagnosis of diseases such as cancer and HIV may significantly reduce the morbidity and mortality of the disease. These assays are cost effective, facile and reproducible. Commonly used protein assay are Bradford, Lowry, BCA, and UV spectroscopic protein assays. Thus, use of assay in disease diagnosis, drug discovery and development encourages the biotechnology and pharmaceutical industry to invest in R&D, which fuels the demand of protein assays market.

Several new biomarker identification systems are launched by the key players which grants various opportunities for the global protein assay market. For instance, in June 2017, Gyros Protein Technologies AB launched a new version of its anti-drug antibody (ADA) solution for the immunogenicity market. This solution enables customers to automatically run the assays in a time-efficient manner using small volumes of patient samples and reagents, and shorten run-times.

According to a publication by Pharmaceuticals Research and Manufacturers of America (PhRMA), the organizations spent approximately $58.8 billion on R&D in 2015 accounted for the largest part of all the biopharmaceutical R&D spending in the U.S. However, high cost of multiplex assay hardware is limiting the growth of global protein assay market.

The global protein assays market is expected to grow at a CAGR of approximately 10.8% during the forecast period 2017-2023.

Segmentation

The protein assays is segmented on the basis of type, application, product, technology and end-users.

On the basis of type, the market is segmented into copper-ion-based assays, test strip-based assays, dye-binding assays, and others

On the basis of application, market is segmented into diagnosis, drug discovery, protein purification and others

On the basis of product market is segmented into reagents & kits, instruments and others

On the basis of technology, market is segmented into colorimetric-based protein assays, fluorescence-based protein assays, and absorbance-based protein assays

On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.

Regional Analysis

The global protein assays market consists of countries namely America, Europe, Asia Pacific, and the Middle East.

North America is projected to hold the largest share of the global protein assay market due to presence of superior research and development base, strong regional economics, and greater emphasis on disease prevention and wellness by governments.

The European protein assay market is expected to witness rapid growth owing to the high investment in various private and government funded research and development programs in the region and increased spending on pharmaceutical and biotechnology industry development.

Countries such as China, Japan, and India in Asia Pacific are also poised to be promising markets for protein assay in the near future. The healthcare expenditure in Asia increased due to an extension of state health care programs and the increasing affluence of the population. India is anticipated to witness an expansion in spending due to a government resolution to enhance healthcare services. Moreover, China and South Korea are striving to develop their biotechnology sector for diagnosis purpose. China’s efforts to develop its biotech sector has shown good results in sectors such as vaccines and biological products and the same can be expected in the protein assays industry. However, low research and development (R&D) yields, high infrastructure cost, stringent regulatory framework, and lack of trained resources are some of the restraints of the protein assay market.

The Middle East region is expected to grow at a faster rate due to the factors such as the extensive development of health care infrastructure and growing emphasis on research and development in the health care sector.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/protein-assays-market-5091

Hypotonia Market Expected To Grow At High Cagr During Forecast Period 2020 – 2023

 Hypotonia is also known as floppy baby syndrome, or weakness of muscles and lack of muscle tone.   There are two main types of hypotonia – Acquired hypotonia in which hypotonia develops after birth as the result of an underlying medical condition, injury or trauma; and congenital hypotonia in which hypotonia is present at birth. Hypotonia is a symptom rather than a condition. Major causes of hypotonia can either be neurological or non-neurological.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4949

Hypotonia is characterized with diminished muscle tone. The infant or child with hypotonic cerebral palsy appears floppy like a rag doll, hence the name. Hypotonic cerebral palsy is the result of an injury or malformation at an earlier brain developmental stage than that which causes spastic or choreoathetoid cerebral palsy. There are various causes of cerebral palsy which includes brain injury or brain malformation that occurs while the brain is developing i.e before, during, or after birth. As a result of the brain damage, during brain development, a child’s muscle control, muscle coordination, muscle tone, reflex, posture and balance can be affected.

Neurological problems present at birth which affect a child’s movement and co-ordination of brain and spinal cord injury including bleeding in the brain.

According to the World Health Organization estimates, neurological disorders are responsible for 4.5%-11% of all illnesses in the world including low or high income economies. This is far higher as compared to the number of respiratory ailments, gastrointestinal disorders, or cancers, and the burden is expected to increase further over the coming years.

However, limited availability of facilities and higher treatment cost may hamper the market growth during the forecast period.

The global hypotonia market is expected to grow at a CAGR of ~5.8% during the forecast period 2017-2023. 

Intended Audience

• Pharmaceutical and Biotechnological Companies
• Research and Development (R&D) Companies
• Ambulatory Care Centers
• Academic Institutes and Universities
• Market Research and Consulting Service Providers
• Potential Investors 

Segmentations

The global hypotonia market is segmented on the basis of types, diagnosis, treatment, and end user.

On the basis of the type, it is segmented into acquired hypotonia and congenital hypotonia.  

On the basis of diagnosis it is segmented into physical examination, blood tests, muscle biopsy, assessment of cerebrospinal fluid, computerized tomography or CT scan or magnetic resonance imaging (MRI) scan, electroencephalogram, electromyography, metabolic panel tests, assessment of thyroid hormone, nerve conduction velocity, genetic testing, and others.

On the basis of treatment, it is segmented into physiotherapy, occupational therapy, speech and language therapy, drugs, and others. Drugs is further segmented into neostigmine, physostigmine, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research laboratories and others.

Regional Analysis

The Americas dominate the global hypotonia market owing to well-developed technology, increasing patient population, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds second position in the global hypotonia market owing to government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, developed economies of the region such countries such as Germany and France are increasing investment in the healthcare domain and are focusing more on hospital infrastructure.    

Asia Pacific is the fastest growing hypotonia market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing patient population in countries like India and South Korea are likely to emerge as the fastest growing market across the globe. Furthermore, increasing demand for quality devices in the healthcare is projected to lead the use of advanced equipment, which, in turn, may increase the market growth in this region.

On the other hand, the Middle East & Africa holds the least share of the market owing to less availability of funds, limited medical facilities, and deprived political conditions in Africa.

Key Players

Some of key the players in the market are LivaNova PLC (U.K), EnteroMedics Inc. (U.S.), ElectroCore Medical LLC (U.S.), Boston Scientific Corporation (U.S.), Cyberonics, Inc. (U.S.), NeuroMetrix, Inc.(U.S.), ImThera Medical (U.S.), and Inspire Medical Systems, Inc.(U.S.), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hypotonia-market-4949

Top Trends In EMEA Gastrointestinal Drugs Market By 2023

 Gastrointestinal (GI) drug market is a growing market in Europe and Middle East and Africa. As per study it was estimated that ~ 6% of total European population is suffering from minor or major gastrointestinal problems. Gastroesophageal reflux is the most common disease and is responsible for generating a good market. The major driving factor for this market are increasing prevalence of many gastrointestinal disease. In addition to this, technological advances, infrastructure development increasing investment in research activity and increasing awareness about the availability of treatment are responsible for providing fuel for the growth of the market. While incorrect self-diagnosis and availability of many misbranded drug are the major restraining factor for the growth of market.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/608

Europe and Middle East and Africa GI drug market is expected to grow at a CAGR of 4.5% during 2017-2023.

Key Players for Europe, Middle East and Africa Gastrointestinal Drugs market

AstraZeneca Plc.(UK), Johnson & Johnson (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals Inc. (US), Sanofi Ltd. (France), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), AbbVie Inc. (US), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany).
Segmentation
Europe, Middle East and Africa gastrointestinal drugs market has been segmented on the basis of Drug Category they are segmented into Acid Neutralizers, Laxatives and Antidiarrheal, antiemetic, Anti-inflammatory drugs and other. Acid Neutralizers are further sub segmented into Antacids, H2 antagonists, Proton pump inhibitors and others. By Route of Administration they are segmented into Oral, Parenteral and rectal. By disease type they are segmented into Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other. By End User Hospital Pharmacies, Retail Pharmacies and Other

Regional Analysis
Europe is the second major contributor in the GI drug market globally. Total Europe and Middle East and Africa GI drug market in 2016 was approximately USD$ 15 million. Germany and France are the major contributor of the market this is due to a huge number of patient suffering from different GI problems. About 9.2% of total population in France is suffering from acute or chronic GI problems. This is the major factor responsible for the growth of market. Due to saturation of market in this region the market is growing at a steady CAGR of 4.5 % during 2017-2023.

The report for Europe, Middle East and Africa Gastrointestinal Drugs Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/europe-gastrointestinal-drugs-market-608

Top Trends In Laser Therapy Market By 2023

 Laser therapy is a non-invasive medical treatment that uses light of a specific wavelength to treat multiple diseases. Laser therapy is most commonly used to remove tumors or precancerous growths, remove kidney stones, repair a detached retina, treat hair loss, and various cancers. Laser treatment is also used to seal nerve endings after surgery, lymph vessels to reduce swelling, and blood vessels to help prevent blood loss. Lasers have become an essential part of the ophthalmology. In laser-based ophthalmology, a beam of light reshapes the cornea, thereby improves the corneal focusing. It can also be used to create a channel to relieve the intraocular pressure of glaucoma or cauterize tiny hemorrhages. Commonly used lasers in ophthalmology are Nd: YAG LASER, excimer LASER, femtosecond LASER, and others. Increasing prevalence of the diseases like cataract and arthritis is the major driver for the market growth. According to the National Eye Institute, the number of people in the U.S. with cataract is expected to double from 24.4 million in 2010 to 50 million by 2050. Moreover, in 2015, National Eye Institute stated that more than half of the Americans suffer from a cataract related problems in their life span. Moreover, growing demand for aesthetics and rising geriatric population followed by increasing demand for non-invasive procedures wil arket growth during the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/3812

The global laser therapy market is expected to grow at a CAGR of 9.2% during the forecast period.

Segmentation

The global laser therapy market is segmented on the basis of type and application.

On the basis of type, the market is segmented into diode lasers, solid state lasers, gas lasers, dye lasers, and others.

On the basis of application, the market is segmented into dermatology and aesthetics, surgery, dental, and others. The surgery segment is further segmented into urology, ophthalmology, and others.

 

Regional Analysis

America dominates the global laser therapy market owing to a well-developed healthcare sector. Moreover, huge patient population for medical conditions like arthritis and cataract, drives the market growth. According to the Centres for Disease Control and Prevention, about 78 million U.S. adults aged 18 years or older are projected to have doctor-diagnosed arthritis by 2040. Additionally, changing lifestyle, increasing healthcare expenditure, and growing geriatric population have boosted the growth of the market in America.

Europe is the second largest laser therapy market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, increasing healthcare expenditures, a well-developed healthcare sector and government support for research & development are projected to drive the market growth during the forecasted period. According to the Royal National Institute of Blind People (2016), the number of people living with sight loss are expected to reach 2.7 million by 2030 due to possible cases of refractive error, cataract, glaucoma, and others.

Asia Pacific is the fastest growing region in the global market due to the presence of a huge patient population, continuously developing economies like India and China which are presenting great opportunities to the market. Moreover, growing geriatric population within the region boosts the market growth. According to the Economic and Social Commission for Asia and the Pacific, in 2016 about 12.4% of the population within the region aged 60 or more and this geriatric population is expected to reach 1.3 billion by 2050.

On the other hand, the Middle East & Africa hold the least share in the global laser therapy market due to presence of poor economy and stringent government policies, especially, in the African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/laser-therapy-market-3812

Paroxysmal Atrial Tachycardia Market In Depth Study And Analysis Published, 2023

 The global paroxysmal atrial tachycardia market is expected to reach USD 10.7 billion by 2023, and the market is projected to grow at a CAGR of ~ 6.5 % during the forecast period 2017-2023.

Paroxysmal atrial tachycardia is irregular heartbeat and is a type of atrial arrhythmia where the episode of arrhythmia begins and ends abruptly. Paroxysmal atrial tachycardia (PAT) is also known as paroxysmal supraventricular tachycardia (PSVT). PAT increases heart rate from 60 to 100 beats per minute (bpm) to between 130 and 230 bpm with infants demonstrating heart rate greater than 220 bpm. PAT is the most common form of tachycardia in infants and children. Symptoms of PAT may include palpitations, lightheadedness, sweating, shortness of breath, chest pain and others. PAT is not usually a life-threatening disorder and the symptoms subside on their own. However, in rare cases, PAT may cause unconsciousness, congestive heart failure, cardiomyopathy and cardiac arrest. Having other heart issues such heart attacks or valve disease increase risk for PAT.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4910

The cause of PAT are unknown but risk factors include alcohol, caffeine, nicotine, psychological stress, and Wolff-Parkinson-White syndrome. PAT occurs when electrical signals starting in the heart’s atria fire irregularly which affects the electrical signals transmitted from the sinoatrial node. This irregular beating prevents your heart from having enough time to fill with blood before pumping blood resulting in the body not receiving enough blood or oxygen. Women are at a higher risk for PAT than men.
Key Players in the Global Paroxysmal Atrial Tachycardia Market
Some of the key players profiled in the report are Abbott Laboratories, Reliant Pharmaceuticals, BIOTRONIK SE & Co. KG, Boston Scientific Corporation, GlaxoSmithKline plc, GE Healthcare, Glenmark Pharmaceuticals, Koninklijke Philips N.V., ANI Pharmaceuticals, Inc., Medtronic, Inc., Microport Scientific Corporation, St. Jude Medical, Inc., and Siemens AG and others.

The market drivers for global paroxysmal atrial tachycardia market are rise in demand due to growing older population, increasing screening, greater emphasis on cardiac treatment, urgency of the paroxysmal atrial tachycardia treatment, rise in risk factors and others. The market restraints are the complications such as risk of bleeding, infections, pain, especially during surgery, high cost of paroxysmal atrial tachycardia treatment, lack of cardiac care infrastructure, and lack of focus on other diseases by the developing regions and others.

Segments
The global paroxysmal atrial tachycardia market has been segmented on the basis of types, condition, diagnosis, drugs, surgery and end user.

Based on the types, the market has been segmented as AV nodal re-entrant tachycardia (AVNRT), AV reciprocating tachycardia (AVRT), and paroxysmal atrial tachycardia.

Based on the diagnosis, the market has been segmented as electrocardiogram (ECG), echocardiogram, blood tests, and electrophysiology study (EPS) and others.

Based on the treatment, the market has been segmented as calcium channel blockers, digoxin, beta-blockers, anti-arrhythmic medications, surgical ablation and others.

Based on the end user, the market has been segmented as hospitals and clinics, research and academics and others.

Regional Analysis
The Americas account for a significant market share owing to high expenditure on the health care especially in the U.S. and Canada. Additionally, the greater number of cardiac procedures due to greater healthcare penetration in the U.S. and Canada drives the paroxysmal atrial tachycardia market. The high concentration of the major hospitals in the developed countries of this region coupled with good reimbursement rates is also adding fuel to the market growth. Moreover, the large share of cardiac procedures especially the cardiac surgery treatment in the returns of hospitals favors the market. The large number of pharmaceutical companies in the U.S. is also a cause for the faster development of paroxysmal atrial tachycardia market in the U.S. The high development of microsurgery field in developed regions such as the U.S. and Europe is a strong driver of the market.

Europe is the second largest market in the world due to growing pharmaceutical industry and healthcare penetration. The European market growth is led by countries such as Germany and France. Germany is expected to be the fastest growing market over the assessment period due to its large pharmaceutical and microsurgery devices industry.

Asia Pacific region is expected to grow rapidly; China and India are likely to lead this market due to the fast growing healthcare sector and large unmet needs over the forecast period. South East Asian countries such as China, India, and Malaysia are projected to contribute highly to the market growth. The growing penetration of healthcare industry in the Asia Pacific region is expected to drive the future paroxysmal atrial tachycardia market in the region. However the low expenditure on cardiac and eye care coupled with the lack of insurance penetration in the developing regions is a dent on the market.

Gulf nations such as Saudi Arabia and the UAE are estimated to drive the Middle East & African market. Other Middle East nations to watch out for are Kuwait, Jordan, Egypt and Iran. The African region is expected to witness a poor growth owing to poor economic and political conditions, and poor healthcare development. Other regions are expected to be laggards due to poor social development and tribal identities such as sub Saharan Africa. The focus of the governments of poor countries on fulfilling basic healthcare relegates the paroxysmal atrial tachycardia market to the background which hampers the development of the market.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/paroxysmal-atrial-tachycardia-market-4910

Cancer Biological Therapy Market 2020 Market Challenge, Driver, Trends & Forecast To 2023

 Market Research Future (MRFR) evaluates that the Cancer Biological Therapy Market can touch an impressive USD 82,276.8 Million by 2023-end. MRFR also projects that the global cancer therapeutics market can attain a growth rate of 4.7 % from 2017 to 2023 (forecast period).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/566

Drivers

Escalating Cancer Cases and Rising Use of Nanotechnology to Boost Growth

Significant burden of rising cancer cases and the surging death rate across the world have been major reasons for the strong growth of the cancer biological therapy market. The World Health Organization (WHO) says that cancer is one of the top five causes of death globally and claimed over 9.5 million lives in 2018 alone. Some key factors that result in cancer development can be the accelerated intake of tobacco and alcohol, which further strengthen the cancer biological therapy industry.

Researchers and vendors in the global cancer biologics market are increasingly making use of nanotechnology to develop more innovative and effective treatment options for patient. This procedure is touted to be a game-changer for cancer diagnosis, while the advancements in materials science, as well as protein engineering, could be huge assets for medical professionals in precise targeting of cancer cells. These innovations are gaining considerable grounds backed by increasing government spending and favorable policies across developed countries.

Opportunities

Rising Education and Awareness Levels to be a Significant Opportunity

Gene therapy has emerged as a lucrative opportunity for the prominent firms in the market, considering the host of benefits compared to other traditional cancer therapies along with the rising advances in this field. The surge in biotechnological funding encouraging extensive R&D activities with respect to cancer gene therapy are expected to be significant cancer biological therapy market trends in the ensuing years.

Restraints

Huge Spending Required on Drug Development to Slow Down Growth

Requirement for substantial funds for effective drug development discourages industry participants, in turn slowing down the market growth.

Challenges

Risks Associated with Anti-Cancer Drug Therapies

In some cases, complications arise from anti-cancer drug therapies, which bring down the success rate of the overall treatment. In view of these risks, the demand for cancer biological therapy could weaken and prove to be a significant challenge over the following years.

Segment Overview

Phase III to Capture the Largest Share

The various phases in clinical trials include phase I, phases II and phases III.  Generally, the clinical trials’ success rate increases from phase I to phase II and lastly phase III, and therefore, the phase III is expected to take the lead in the global market. Phase 3 clinical trials involve huge number of candidates in order to ensure the validity of the result.

Monoclonal Antibodies to Claim the Leading Position

Primary types considered in the MRFR report are interferons, monoclonal antibodies, cancer growth inhibitors, interleukins, colony-stimulating factors and gene therapy. Monoclonal antibodies segment should project the highest growth in the coming years, as these have the ability to target certain proteins present on the cell surface, leading to its escalating use in cancer treatment. Also, greater preference for innovative cancer biological therapies to reduce the risk related to anti-cancer drug therapies will also mean substantial growth for the segment.

Hospitals & Clinics to be the Top End-User

Some of the key market end-users include cancer research centers and laboratories as well as hospitals & clinics. Hospitals & clinics lead the worldwide industry owing to their rising number across developing countries and the availability of a vast range of medical devices for treatment and surgeries. However, there has been striking growth in the number of cancer research centers and laboratories as well, backed by substantial funding by the government and private firms worldwide.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cancer-biologic-therapy-market-566

Latest Study Offers Detailed Insights On Eyelashes Enhancing Market 2023

 Eyelash enhancing serum is a unique formula with lash enhancement, conditioning, moisturizing, and strengthening ingredients that collaboratively works to support and improve the overall appearance of eyelashes. A plenty of temporary lash-lengthening options are available in the market such as mascara and false eyelashes, which are available in the market, but there has been an influx of eyelash serums in stores that promise to strengthen and grow those tiny hairs. These eyelash enhancers have become increasingly popular due to their effective functional feature that turns drab, sparse, and brittle eyelashes into attractive and long eyelashes by the simple process of applying serums to the eyelash area. 

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4862

The global eyelashes enhancing agents market is growing moderately due to increasing prevalence of eye inflammations such as madarosis and blepharitis. Additionally, a shift in trend towards the natural eyelash enhancer agent, and continuous uptake of come higher medical dosages cause loss of eyelashes is likely to drive the market growth over the review period.

Breast cancer patients suffer from madarosis due to continuous session of intra-arterial chemotherapy. To cure this disease, a formulation of eyelash enhancer such as bimatoprost is used that maximizes eyelash and minimizes intraocular side effect. In case of blepharitis, there is loss of eyelashes occurs due to the presence of bacteria and oily flakes at the base of eyelashes. Blepharitis is a common disease, especially, among people who have oily skin, dandruff or dry eyes. According to International Journal of Development Research, blepharitis accounted for 700,000 patient visits in the US in 2014. Patients who have blepharitis take eyelash enhancer such as biotin as part of treatment. In some cases, blepharitis also causes loss of eyelashes (madarosis).

However, side-effects of eyelashes enhancer agents may affect the growth of the global eyelashes enhancing agents market, negatively.

The global eyelashes enhancing agents market is expected to grow at a CAGR of 5.83% during the forecast period 2017-2023.

Segmentation                                                                                                                                      

The global eyelashes enhancing agents market is segmented on the basis of types, application, and content.

On the basis the types, it is segmented into curling, lengthening, volumizing, and others.

On the basis of the application, it is segmented into repairing damaged eyelashes, nourishing, and others.

On the basis of the content, it is segmented into bimatoprost, lash-building serum, skincare ingredients, herbal remedy, isopropyl cloprostenate, enhancer serum, and others. The skincare ingredients are further segmented into polypeptides, biotin, panthenol, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/eyelashes-enhancing-agents-market-4862